Global BioLife Inc.’s Naturally Modified Sugar Laetose(TM) Unveiled at Harvard Global Health Summit
SGX-listed Singapore eDevelopment Ltd (“SeD”, SGX:40V) is pleased to announce the results of clinical trials conducted on Laetose(TM), a low-glycemic, naturally modified sugar, developed by its U.S. biomedical subsidiary Global BioLife Inc. (“Global BioLife”). Clinical trial results show that Laetose is a new sugar